Related Experiment Video
Updated: Jul 5, 2026
07:43
Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
TSH-secreting adenoma improved with cabergoline
F Mouton1, F Faivre-Defrance, C Cortet-Rudelli
1Service d'endocrinologie et métabolisme, CHU de Lille, 6, rue du Pr Laguesse, 59037 Lille cedex, France.
Annales D'Endocrinologie
|May 20, 2008
Summary
Thyroid-stimulating hormone (TSH)-secreting pituitary adenomas are rare. This study highlights cabergoline as a surprising and effective treatment for a resistant case, suggesting its potential in challenging pituitary adenoma treatments.
Area of Science:
- Endocrinology
- Oncology
- Neurosurgery
Background:
- Thyroid-stimulating hormone (TSH)-secreting pituitary adenomas are rare, comprising 0.5-2.5% of pituitary tumors.
- Clinical presentation includes thyrotoxicosis, goiter, and compressive symptoms.
- Diagnosis involves elevated free T4/T3, inappropriately normal/high TSH, and increased alpha-subunit levels.
Observation:
- Magnetic resonance (MR) imaging is crucial for diagnosis, with resistance to thyroid hormones as a key differential.
- Standard treatments include surgery, somatostatin analogs, and radiotherapy.
- A specific case demonstrated resistance to stereotactic radiotherapy and somatostatin analogs.
Findings:
- The resistant pituitary adenoma case showed a surprising improvement with cabergoline treatment.
- This suggests cabergoline's efficacy in managing TSH-secreting adenomas.
- The patient's condition improved despite resistance to conventional therapies.
Implications:
- Cabergoline may represent a viable alternative treatment for refractory TSH-secreting pituitary adenomas.
- Further research is warranted to explore cabergoline's role in managing challenging pituitary adenoma cases.
- This finding could improve long-term outcomes for patients with rare pituitary tumors.
Related Concept Videos
01:20Synthesis and Regulation of Thyroid Hormones
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
01:27Goiter
Goiter refers to an abnormal enlargement of the thyroid gland that may appear as a diffuse goiter (uniform enlargement) or nodular (single or multiple nodules). Functionally, it is classified as nontoxic (normal/low hormone levels) or toxic (excess hormone production).PathophysiologyDiffuse thyroid enlargement typically results from prolonged stimulation by thyroid-stimulating hormone (TSH) or TSH-like agents, commonly seen in hypothyroidism or iodine deficiency. In contrast, in hyperthyroid...
01:25Hyperthyroidism I: Introduction
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
01:23Hypothyroidism II: Pathophysiology
Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
01:24Graves Disease II: Pathophysiology
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...